(TFX) Teleflex - Ratings and Ratios

Teleflex Incorporated (NYSE:TFX) is a global leader in the design, development, manufacture, and supply of single-use medical devices, primarily serving critical care and surgical applications. The companys product portfolio includes vascular access devices such as Arrow-branded catheters, intraosseous bone access systems, and blood pressure monitoring solutions. It also offers interventional products, including coronary catheters, structural heart support devices, and mechanical circulatory support systems. Anesthesia products, surgical instruments like ligating clips and fascial closure systems, and urology solutions such as the UroLift System for treating lower urinary tract symptoms are key components of its offerings. Additionally, Teleflex provides respiratory care products, including oxygen therapy and ventilation management systems, and operates in the OEM market through brands like TFX Medical OEM and Deknatel. The company serves hospitals, healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania. Web URL: https://www.teleflex.com.

Teleflex has established itself as a critical player in the medical device industry, with a strong focus on innovation and patient outcomes. Its diverse product range addresses a wide spectrum of clinical needs, from vascular access and interventional cardiology to surgical and respiratory care. The companys commitment to research and development has enabled it to maintain a competitive edge, particularly in high-growth areas such as minimally invasive procedures and home healthcare solutions. Teleflexs global footprint and extensive distribution network further enhance its ability to meet the evolving demands of healthcare providers worldwide.

3-Month Forecast: Based on and , Teleflexs stock is expected to experience moderate volatility with a neutral to slightly negative bias. The SMA 20 (133.12) and SMA 50 (142.29) suggest short-term support at current levels, while the SMA 200 (193.89) indicates longer-term downward pressure. The ATR of 4.14 signals moderate price movement. Fundamentally, the high P/E ratio (88.21) compared to the forward P/E (9.41) suggests expectations of future earnings growth. However, the low RoE (1.63%) and P/S ratio (1.93) may indicate challenges in profitability and revenue efficiency. Overall, the stock is likely to trade in a range between 125 and 140, with potential resistance at 142.29 and support at 133.12.